NASDAQ$WHWK
Whitehawk Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Aadi Bioscience reported FYARRO sales of $5.4 million, reflecting distributor ordering patterns and fewer commercial patient initiations, while also progressing with the PRECISION1 trial and Phase 2 trials in EEC and NETs.
Aadi Bioscience reported total revenue of $5.4 million for Q1 2024, primarily from FYARRO sales. The company experienced a net loss of $18.3 million. Key developments include the full enrollment of the PRECISION1 trial and ongoing enrollment in Phase 2 trials for EEC and NETs.
- FYARRO net product sales were $5.4 million in Q1 2024, an 8.8% decrease year-over-year.
- PRECISION1 trial is now fully enrolled, with a two-thirds interim analysis expected in Q3 2024.
- Enrollment is ongoing in two Phase 2 trials investigating nab-sirolimus for EEC and NETs.
- Cash, cash equivalents, and short-term investments were $88.3 million as of March 31, 2024, expected to fund operations into Q4 2025.
Headline financials
Revenue & EPS history
Aadi Bioscience · Revenue · Quarterly
$5.35M
Revenue by segment
Aadi Bioscience · $5.96M total across 1 segment · Q3 2023
- Product Sales, Net$5.96M—100.0%
Forward guidance
Aadi Bioscience expects to provide the two-thirds interim analysis for PRECISION1 in Q3 2024 and anticipates initial data from Phase 2 trials in EEC and NETs later this year. The company expects to return to sales growth in Q2.
Tailwinds
- PRECISION1 trial is fully enrolled.
- Phase 2 trials in EEC and NETs are enrolling well.
- FYARRO has cemented its position as the preferred treatment for malignant PEComa.
- Company expects to return to sales growth in Q2.
- Cash runway extends into Q4 2025.
Headwinds
- FYARRO sales decreased by 8.8% compared to the prior year period.
- Decrease reflects impacts from distributor ordering patterns.
- Decrease reflects fewer new patient initiations than the historical average.
- Net loss for the quarter was $18.3 million, compared to $15.2 million for the same period last year.
- Termination of collaboration and clinical supply agreement with Mirati/Bristol Myers Squibb.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.8%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+4.1%
Avg return
30 days after
37%
11 / 30 earnings
Positive
+69.8%
Q1 2021
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -5.5% | -0.7% | |
| Q3 2025 | -0.4% | -3.5% | +10.2% | |
| Q1 2025 | +4.9% | -4.0% | -9.5% | |
| Q4 2024 | -1.5% | +1.2% | +14.7% | |
| Q3 2024 | +5.5% | +5.5% | +21.6% | |
| Q2 2024 | -3.6% | -1.4% | +30.7% | |
| Q1 2024 | -10.9% | -11.4% | -17.5% | |
| Q4 2023 | +5.7% | +9.3% | +1.0% | |
| Q3 2023 | -6.6% | -5.4% | +2.9% | |
| Q2 2023 | -1.0% | +1.7% | -12.2% | |
| Q1 2023 | -18.7% | -17.2% | -4.7% | |
| Q4 2022 | -1.8% | -0.1% | +10.3% | |
| Q3 2022 | +5.1% | +1.2% | +1.7% | |
| Q2 2022 | -6.2% | -0.9% | -11.0% | |
| Q1 2022 | +21.2% | +30.1% | +21.5% | |
| Q4 2021 | +5.4% | +2.3% | -8.2% | |
| Q3 2021 | -16.6% | -8.9% | -13.4% | |
| Q2 2021 | +3.0% | +2.0% | -7.9% | |
| Q1 2021 | +69.8% | +74.1% | +69.0% | |
| Q4 2020 | +1.9% | +2.5% | -15.1% | |
| Q3 2020 | -2.2% | +21.7% | +60.9% | |
| Q2 2020 | +17.3% | +6.4% | -22.4% | |
| Q1 2020 | -0.2% | -1.3% | +82.3% | |
| Q4 2019 | -5.8% | -17.7% | -6.2% | |
| Q3 2019 | -2.6% | -3.6% | +0.9% | |
| Q2 2019 | -1.9% | -1.9% | +0.9% | |
| Q1 2019 | -0.9% | -1.9% | -5.7% | |
| Q4 2018 | +4.2% | +22.4% | -65.0% | |
| Q3 2018 | -1.4% | -11.7% | -2.3% | |
| Q2 2018 | -1.7% | +3.9% | -3.8% | |
| Q4 2011 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro